P-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

Neuroscience Letters

Volumn 575, Issue , 2014, Pages 96-100

  Walls, Ken C ^a   Ager, Rahasson R ^a   Vasilevko, Vitaly ^a   Cheng, Dave ^a   Medeiros, Rodrigo ^a   LaFerla, Frank M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Immunotherapy; Neurofibrillary tangles; Phosphorylated tau; Tau

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G8; MONOCLONAL ANTIBODY AT8; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; ANTIBODY; APP PROTEIN, HUMAN; EPITOPE;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEMISPHERE; HIPPOCAMPUS; IMMUNIZATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MALE; MOUSE; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SILVER STAINING; ALZHEIMER DISEASE; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; EPITOPES; IMMUNOTHERAPY; MICE, TRANSGENIC; PHOSPHORYLATION; TAU PROTEINS;

EID: 84902524301     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.05.047     Document Type: Article

References (29)

1. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
2. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
3. Dumanchin C., Camuzat A., Campion D., Verpillat P., Hannequin D., Dubois B., Saugier-Veber P., Martin C., Penet C., Charbonnier F., Agid Y., Frebourg T., Brice A. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum. Mol. Genet. 1998, 7:1825-1829.
4. Goedert M., Klug A., Crowther R.A. Tau protein, the paired helical filament and Alzheimer's disease. J. Alzheimers Dis. 2006, 9:195-207.
5. deCalignon A., Polydoro M., Suarez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., Pitstick R., Sahara N., Ashe K.H., Carlson G.A., Spires-Jones T.L., Hyman B.T. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
6. Clavaguera F, Bolmont T., Crowther R.A, Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol,11 2009, 909-913.
7. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
8. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
9. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006, 281:39413-39423.
10. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., Holtzman D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:6213-6220.
11. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010, 120:369-384.
12. Serrano-Pozo A., William C.M., Ferrer I., Uro-Coste E., Delisle M.B., Maurage C.A., Hock C., Nitsch R.M., Masliah E., Growdon J.H., Frosch M.P., Hyman B.T. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010, 133:1312-1327.
13. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
14. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
15. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
16. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F, Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
17. Bi M., Ittner A., Ke Y.D., Gotz J., Ittner L.M. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011, 6:e26860.
18. Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckburner H., Hanmer J., Daves P., O'Neil M.J., Mutton M.L., Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 2011, 286:34457-34467.
19. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 2010, 30:16559-16566.
20. Goedert M., Jakes R., Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995, 189:167-169.
21. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
22. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 2010, 224:472-485.
23. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
24. d'Abramo C., Acker C.M., Jimenez H.T., Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013, 8:e62402.
25. Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011, 118:658-667.
26. Nerenberg S.T., Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J. Lab. Clin. Med. 1975, 86:887-898.
27. van der Kleij H., Charles N., Karimi K., Mao Y.K., Foster J., Janssen L., Chang Yang P., Kunze W., Rivera J., Bienenstock J. Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors. J. Allergy Clin. Immunol. 2010, 125:757-760.
28. Krishnamurthy P.K., Deng Y., Sigurdsson E.M. Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model. Front. Psychiatry 2011, 2:59.
29. de Calignon A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., Hyman B.T. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.